ProQR will host an investor webcast on May 9, 2024 at 8:00 am EDT with members of the ProQR Management Team to highlight the data being presented in the ASGCT 2024 poster session and will also conduct an analyst Q&A session.
This virtual event on March 29, 2023 featured presentations by ProQR Management on the company's proprietary Axiomer® RNA editing technology platform, detailed the initial pipeline targets, and provided guidance on the advancement of programs toward the clinic. ProQR also reported its 2022 year-end financials and the extension of its cash runway guidance.
ProQR will host a virtual Investor and Analyst Event highlighting its pipeline entitled:
“Expanding the Axiomer™ RNA Editing Opportunity Beyond AX-0810”
The 2021 annual general meeting (AGM) of shareholders of ProQR Therapeutics
will take place on Wednesday, May 19, 2021, at 16:00 hours CET/10:00am EDT.
This is Gerard Platenburg's presentation at the 5th International Conference on Base Editing, Prime Editing & Related Enzymes (Deaminet 2024) in San Diego, California.
